HER2 and YAP co-expression amplifies an autocrine growth-factor program that confers growth-factor independence in HER2-positive breast cancer
HER2-targeted therapies have improved outcomes in HER2-positive breast cancer, yet ~ 20% of tumours recur within five years and the mechanisms underlying the aggressive, treatment-resistant subset are incompletely defined. The Hippo-pathway effector YAP is implicated in this subset; here we explored the mechanistic role of YAP in HER2-driven aggressive oncogenic features using cell lines as a model system. We examined YAP expression by immunohistochemistry in 76 HER2-positive primary breast tumours with clinical follow-up. To dissect mechanism, we generated MCF10A mammary epithelial cell lines stably overexpressing HER2 and/or YAP and shYAP lines in both the parental and the HER2 background, and characterised proliferation, migration and signalling in complete and in growth-factor-reduced media. Whole-transcriptome RNA-sequencing was performed across all eight engineered lines. Combination treatments with verteporfin, dasatinib, trastuzumab and lapatinib were tested in SKBR3 and ZR-75-1 cells; YAP-target growth-factor transcripts were measured by RT-qPCR. In the patient cohort, high YAP expression showed numerical trends toward aggressive features (residual disease after NACT, recurrence, shorter disease-free survival), though none reached statistical significance in this underpowered cohort. In MCF10A, HER2 + YAP co-expression produced a significant but modest cooperative effect on proliferation and migration under standard growth conditions. Under growth-factor-reduced conditions, the cooperation became markedly synergistic, consistent with acquisition of autocrine self-sufficiency. YAP knockdown in the HER2 background reversed the proliferation and migration phenotypes and sensitised cells to trastuzumab. RNA-sequencing identified 238 genes synergistically up-regulated by HER2 + YAP and reversed by YAP knockdown, heavily enriched for autocrine growth factors (AREG, IL6, FSTL1, CCN1, CCN2/CTGF), chemokines and extracellular matrix components. In SKBR3 and ZR-75-1 cells, combined verteporfin + trastuzumab produced greater growth inhibition than either agent alone with concomitant down-regulation of the same autocrine growth factors. We describe a co-regulated YAP–HER2 transcriptional output that amplifies an autocrine growth-factor loop, as a candidate mechanism for the aggressive subset of HER2-positive disease with high YAP expression. These data provide preclinical rationale for combined YAP and HER2 inhibition; they do not establish a validated co-targetable vulnerability. Validation in HER2-amplified and trastuzumab-resistant models, in vivo, and ultimately in patients stratified by YAP expression is required.
Authors
- Tuan Zea Tan (ORCID: https://orcid.org/0000-0001-6624-1593)
- Chaitanyanand B. Koppiker (ORCID: https://orcid.org/0000-0002-1363-274X)
- Aditi Sanjay Khatpe (ORCID: https://orcid.org/0000-0001-5652-3351)
- Madhura Kulkarni (ORCID: https://orcid.org/0000-0002-0406-5739)
- Sunitha Manjari Kasibhatla (ORCID: https://orcid.org/0000-0003-0320-2209)
- Rutvi Shah (ORCID: https://orcid.org/0000-0002-2382-9175)
- Anirudha K. Puntambekar
- Neeraj Bharti
- Lingadahalli Subrahmanya Shashidhara (ORCID: https://orcid.org/0000-0001-9306-1432)
- V Gomathi (ORCID: https://orcid.org/0000-0002-1322-5132)
- Shruti Bhardiya
- Bhavesh Vasave
- Khushi Salvi
Institutions
- Indian Institute of Science Education and Research Kolkata (IN)
- Centre for Development of Advanced Computing (IN)
- Ashoka University (IN)
- Prashanti Cancer Care Mission (IN)
- Cancer Science Institute of Singapore (SG)
Publication Details
- Journal
- BMC Cancer
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12885-026-17390-4
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Princeton Center for Complex Materials
- Department of Biotechnology, Ministry of Science and Technology, India